Legato Capital Management LLC Sells 43,769 Shares of Evolus, Inc. (NASDAQ:EOLS)

Legato Capital Management LLC trimmed its holdings in Evolus, Inc. (NASDAQ:EOLS) by 40.3% in the 4th quarter, HoldingsChannel reports. The firm owned 64,778 shares of the company’s stock after selling 43,769 shares during the quarter. Legato Capital Management LLC’s holdings in Evolus were worth $715,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. lifted its holdings in shares of Evolus by 173.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 418,576 shares of the company’s stock worth $6,781,000 after buying an additional 265,635 shares in the last quarter. Ikarian Capital LLC bought a new stake in Evolus in the 3rd quarter valued at $4,184,000. Walleye Capital LLC purchased a new stake in Evolus in the 3rd quarter worth $3,438,000. Lord Abbett & CO. LLC boosted its holdings in shares of Evolus by 23.4% during the 3rd quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company’s stock valued at $16,126,000 after purchasing an additional 188,685 shares during the last quarter. Finally, GSA Capital Partners LLP grew its position in shares of Evolus by 335.3% during the third quarter. GSA Capital Partners LLP now owns 120,964 shares of the company’s stock valued at $1,960,000 after purchasing an additional 93,176 shares in the last quarter. 90.69% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Evolus in a research report on Tuesday, January 21st. Barclays lifted their price objective on Evolus from $20.00 to $22.00 and gave the stock an “overweight” rating in a research note on Monday, January 27th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $27.00 price objective on shares of Evolus in a report on Wednesday, January 22nd.

Evolus Stock Up 5.5 %

Shares of EOLS opened at $15.04 on Friday. The stock has a market capitalization of $952.33 million, a price-to-earnings ratio of -16.53 and a beta of 1.33. Evolus, Inc. has a 1 year low of $9.25 and a 1 year high of $17.82. The business’s 50 day simple moving average is $12.03 and its 200-day simple moving average is $13.96. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.